Drug1st line
Zanubrutinib
Second-generation selective BTK inhibitor
- Response rate
- ~95% ORR; 36% VGPR+CR
- Onset
- Weeks
- Route
- Oral 160mg BID or 320mg daily
- Line
- 1st
- IgM effect
- Significant reduction
- Evidence level
- green
Evidence summary
Next-generation BTK inhibitor with greater selectivity for BTK. The ASPEN phase III trial demonstrated comparable efficacy to ibrutinib with significantly improved safety: less atrial fibrillation (7.9% vs 23.5%), less hypertension, less diarrhea. Currently recommended as preferred first-line BTK inhibitor by Mayo Clinic guidelines.
Approved indications
Conditions for which Zanubrutinib has regulatory approval (not specific to rare diseases covered here):
Waldenström's MacroglobulinemiaCLL/SLLMantle Cell LymphomaMarginal Zone Lymphoma
Drug identifiers
| DrugBank | DB15035 ↗ |
| ATC Code | L01EL03 |
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| BTK (Bruton's Tyrosine Kinase) | Key signaling kinase downstream of MYD88 | Constitutively activated | established |